In a clinical study, patients with advanced lung, colon, or breast cancers treated with G. lucidum for 12 weeks showed increased levels of IL‐2, IL‐6, and IFN‐γ in their plasma and an increased number of CD56+ cells. This evidence concerns the gene IFNG and breast carcinoma.